Trial Profile
A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Rhenium (186Re) obisbemeda (Primary)
- Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
- Sponsors Plus Therapeutics
- 05 Mar 2024 According to a Plus Therapeutics media release, reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites.
- 05 Mar 2024 According to a Plus Therapeutics media release, continue to advance Phase 2 ReSPECT-GBM trial and present data in the second half of 2024.
- 20 Nov 2023 According to a Plus Therapeutics media release, 2024 will be focused on onboarding additional clinical sites, completing Phase 2 enrollment, continuing the Phase 1 trial to maximum tolerated dose, and planning next steps for the program.